Lyon, France – PosterMathilde Jarlier, Immuno R&D engineer, to present a poster entitled “Role of Anti-Nucleoprotein Antibodies in Influenza Protection: Implications for the Development of OVX836, a Broad-Spectrum Influenza Vaccine”. Charlotte Primard, Head of Non-clinical Immunology at Osivax, to present “OVX836, a Nucleoprotein-based vaccine under clinical development, offers protection Against Highly Pathogenic Avian Influenza Viruses …
Tag archives: Event
10th ESWI 2025
Valencia, Spain – Oral PresentationCharlotte Primard, Head of Non-clinical Immunology at Osivax, to provide an update on OVX836 as part of a presentation entitled “OVX836, a Nucleoprotein based vaccine under clinical development, offers protection against Highly Pathogenic Avian Influenza viruses (H5N1 and H7N9) in mouse and ferret models”.
World Vaccine Congress Washington 2025
Washington, DC, USA – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Advancing Influenza Prevention: Latest Clinical Insight on OVX836, a Broad-spectrum T-Cell Influenza Vaccine”.
I4ID 2024
Lyon, France – PosterSéverine Valsesia, Immuno R&D engineer, to present a poster entitled “A mix of OVX836, a NP-based influenza vaccine candidate, with a commercial seasonal vaccine is immunogenic and synergistically protective in mice”. François Fasquelle, Clinical Immunology Project Manager, to present a poster entitled “OVX836, a NP-based broad-spectrum influenza vaccine candidate, is safe, immunogenic …
World Vaccines Congress Europe 2024
Barcelona, Spain – Oral PresentationNicola Groth, Chief Medical Officer, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Update of OVX836, a Novel Broad-Spectrum Type A Influenza Vaccine Candidate”.
Options XII for the Control of Influenza
Brisbane, Australia – Oral Presentation and PostersAlexandre Le Vert, Chief Executive Officer & Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, A NP-Based Universal Influenza Vaccine Candidate, Triggers Effector CD4+ and Cytotoxic CD8+ T-Cells in Healthy Adults”. Delphine Guyon-Gellin, Chief of Business Development & Chief Operating …
ISIDORe User’s conference
Online – Oral PresentationCharlotte Primard, Non-Clinical Project Manager of Osivax, to provide an update on OVX033 as part of a presentation entitled “Immunogenicity, cross-reactivity and poly-functionality of immune responses induced by OVX033 with and without SQ for SARS-CoV-2”.
Influenza Vaccines for the World 2024
Siena, Italy – Oral PresentationNicola Groth, Chief Medical Officer of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.
World Congress Vaccine Washington 2024
Washington, DC – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical development update on OVX836, a T-cell based broad-spectrum influenza vaccine”.